Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sodium nitroprusside
Drug ID BADD_D02046
Description Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
Indications and Usage For immediate reduction of blood pressure of patients in hypertensive crises, reduce bleeding during surgery, and for the treatment of acute congestive heart failure
Marketing Status approved; investigational
ATC Code C02DD01
DrugBank ID DB00325
KEGG ID D00614
MeSH ID D009599
PubChem ID 11953895
TTD Drug ID D07XVR
NDC Product Code 29902-0013; 42571-283; 67457-839; 69097-532; 42533-113; 14789-012; 71839-120; 72485-105; 70121-1189; 52221-111; 59651-172; 14335-132; 25208-003; 71288-202; 64757-0015; 69575-4007; 42973-231; 65571-0020; 70069-261; 70436-028; 14335-133; 55150-320; 72485-305; 14335-130; 43598-587; 51754-1006; 65145-101; 67457-999; 14335-134; 42571-265; 51754-1029
UNII EAO03PE1TC
Synonyms Nitroprusside | Cyanonitrosylferrate | Nitroferricyanide | Nipruton | Nitriate | Nitropress | Nitroprusside, Disodium Salt, Dihydrate | Nipride | Naniprus | Nitroprussiat Fides | Sodium Nitroprusside | Nitroprusside, Sodium | Nitroprusside, Disodium Salt | Disodium Salt Nitroprusside | Ketostix
Chemical Information
Molecular Formula C5H4FeN6Na2O3
CAS Registry Number 13755-38-9
SMILES [C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anxiety19.06.02.002--
Bradycardia02.03.02.002--Not Available
Chest discomfort02.02.02.009; 22.12.02.002; 08.01.08.019--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Electrocardiogram abnormal13.14.05.001--Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperreflexia17.02.01.002--Not Available
Hypothyroidism14.11.01.012; 05.02.03.001--
Ileus07.13.01.001--
Intracranial pressure increased17.07.02.002--Not Available
Methaemoglobinaemia01.05.01.002--
Miosis06.05.03.003; 17.02.11.002--Not Available
Muscle twitching15.05.03.005--Not Available
Nausea07.01.07.001--
Palpitations02.11.04.012--
Platelet aggregation decreased13.01.04.004--Not Available
Rash23.03.13.001--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retching07.01.07.002--Not Available
Tachycardia02.03.02.007--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Infusion site irritation12.07.05.011; 08.02.05.010--Not Available
The 1th Page    1    Total 1 Pages